The test is based on the conversion of lidocaine to its deethylated metabolite monoethylglycinexylidide (MEGX), primarily through the hepatic cytochrome P450 system.
A quick, sensitive high-performance liquid chromatography assay for monoethylglycinexylidide and lignocaine in serum/plasma using solid-phase extraction.
Monoethylglycinexylidide (MEGX), the primary metabolite of lidocaine, is produced via oxidative N-deethylation catalyzed by cytochrome P450 (CYP) 3A4 (1).
Influence of gender on the monoethylglycinexylidide test in normal subjects and liver donors.
The hepatic conversion of lidocaine to the metabolite monoethylglycinexylidide (MEGX)I is primarily catalyzed by the cytochrome P450 enzyme 3A4 in humans (1).
Monoethylglycinexylidide formation kinetics: a novel approach to assessment of liver function.
Use of the rate of formation of monoethylglycinexylidide (MEGX), a metabolite of lidocaine, is being increasingly recognized as an effective method to assess hepatic metabolic function.
(1) Nonstandard abbreviations: PK, pharmacokinetics; PD, pharmacodynamics; DUS, digoxin-like immunoreactive substances; MEGX, monoethylglycinexylidide; and IV, intravenous.
Lidocaine, a commonly used local anesthetic and antiarrythmic agent, is eliminated from the body primarily by hepatic metabolism to monoethylglycinexylidide
Specifically, the kinetics of the lidocaine metabolite monoethylglycinexylidide
(MEGX) can be used to assess hepatocyte injury [22-24].
The hepatic conversion of lidocaine to its metabolite monoethylglycinexylidide
(MEGX) is catalyzed by the cytochrome P450 enzyme CYP3A4 in humans.
For certain compounds such as propoxyphene and its metabolites, diphenhydramine, promethazine, and lidocaine and its major metabolite monoethylglycinexylidide
, Remedi scored remarkably high.